Patents by Inventor Shinsuke Nakao

Shinsuke Nakao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
    Patent number: 11638730
    Abstract: The present invention provides a combination therapy of genetically modified vaccinia virus (particularly oncolytic vaccinia virus) and another cancer therapy for use in treating cancer, and a pharmaceutical composition and a combination kit for use in the therapy. More specifically, the invention provides a therapy with vaccinia virus containing a polynucleotide encoding interleukin-7 (IL-7) and a polynucleotide encoding interleukin-12 (IL-12) in combination with an immune checkpoint inhibitor, and a pharmaceutical composition and a combination kit for use in the therapy.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: May 2, 2023
    Assignee: Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Tatsuya Kawase
  • GENETICALLY ENGINEERED ONCOLYTIC VACCINIA VIRUSES AND METHODS OF USES THEREOF
    Publication number: 20220290179
    Abstract: The present invention provides pharmaceutical compositions comprising an oncolytic vaccinia virus and methods of using such pharmaceutical compositions for treating a subject having a cancer.
    Type: Application
    Filed: August 27, 2020
    Publication date: September 15, 2022
    Inventors: Shinsuke Nakao, Nobuaki Amino, Yukinori Arai
  • CANCER THERAPY BY COMBINATION USE OF ONCOLYTIC VACCINIA VIRUS AND IMMUNE CHECKPOINT INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND COMBINATION MEDICINE FOR USE IN THE CANCER THERAPY
    Publication number: 20210315951
    Abstract: The present invention provides a combination therapy of genetically modified vaccinia virus (particularly oncolytic vaccinia virus) and another cancer therapy for use in treating cancer, and a pharmaceutical composition and a combination kit for use in the therapy. More specifically, the invention provides a therapy with vaccinia virus containing a polynucleotide encoding interleukin-7 (IL-7) and a polynucleotide encoding interleukin-12 (IL-12) in combination with an immune checkpoint inhibitor, and a pharmaceutical composition and a combination kit for use in the therapy.
    Type: Application
    Filed: September 25, 2019
    Publication date: October 14, 2021
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Shinsuke NAKAO, Tatsuya KAWASE
  • Anti-human BDCA-2 antibody
    Patent number: 11046770
    Abstract: [Problem] Provided is an anti-human BDCA-2 antibody for preventing or treating an autoimmune disease by binding to a human BDCA-2 to control the function of a plasmacytoid dendritic cell through human BDCA-2.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: June 29, 2021
    Assignee: Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Masayuki Ito, Yoshiyuki Tenda
  • Genetically engineered vaccinia viruses
    Patent number: 10888594
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 12, 2021
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • Genetically engineered vaccinia viruses
    Patent number: 10849946
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 1, 2020
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • NOVEL GENETICALLY ENGINEERED VACCINIA VIRUSES
    Publication number: 20200338149
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Application
    Filed: July 9, 2020
    Publication date: October 29, 2020
    Applicants: Astellas Pharma Inc., National University Corporation Tottori University
    Inventors: Shinsuke NAKAO, Tatsuya KAWASE, Takafumi NAKAMURA
  • NOVEL ANTI-HUMAN BDCA-2 ANTIBODY
    Publication number: 20190248904
    Abstract: [Problem] Provided is an anti-human BDCA-2 antibody for preventing or treating an autoimmune disease by binding to a human BDCA-2 to control the function of a plasmacytoid dendritic cell through human BDCA-2.
    Type: Application
    Filed: April 15, 2019
    Publication date: August 15, 2019
    Applicant: Astellas Pharma Inc.
    Inventors: Shinsuke NAKAO, Masayuki ITO, Yoshiyuki TENDA
  • Anti-human BDCA-2 antibody
    Patent number: 10294301
    Abstract: [Problem] Provided is an anti-human BDCA-2 antibody for preventing or treating an autoimmune disease by binding to a human BDCA-2 to control the function of a plasmacytoid dendritic cell through human BDCA-2.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: May 21, 2019
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Shinsuke Nakao, Masayuki Ito, Yoshiyuki Tenda
  • NOVEL GENETICALLY ENGINEERED VACCINIA VIRUSES
    Publication number: 20170340687
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 30, 2017
    Applicants: Astellas Pharma Inc., National University Corporation Tottori University
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • NOVEL ANTI-HUMAN BDCA-2 ANTIBODY
    Publication number: 20160319025
    Abstract: [Problem] Provided is an anti-human BDCA-2 antibody for preventing or treating an autoimmune disease by binding to a human BDCA-2 to control the function of a plasmacytoid dendritic cell through human BDCA-2.
    Type: Application
    Filed: December 22, 2014
    Publication date: November 3, 2016
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Shinsuke Nakao, Masayuki ITO, Yoshiyuki TENDA
  • Deadman switch mechanism for emergency stop of robot and teaching operation
    Patent number: 6160324
    Abstract: A deadman switch mechanism and a teaching operation panel equipped with the deadman switch mechanism, in which possibility of losing a safety function is low even if failure happens in a contact or other elements of a circuit. When an operator grips at least one of grip levers (GL1; GL2) with normal force, the grip levers turn around axes (AX4; AX5), shoulder portions (SD1; SD2) abut on slave levers (SL1; SL2) and turns the slave levers connected by a link (LK) around an axis (AX3) in the direction denoted by an arrow B, simultaneously, so that switches (SW1; SW2) are turned into an ON-state, simultaneously. Then, two circuits including those switches, respectively, output ON-signals independently and these signals are subjected to AND process, to allow the robot to operate.
    Type: Grant
    Filed: April 26, 1999
    Date of Patent: December 12, 2000
    Assignee: Fanuc Ltd.
    Inventors: Akihiro Terada, Mitsuhiro Yasumura, Shinsuke Nakao